Camalexin as a treatment for prostate cancer

Inactive Publication Date: 2013-04-18
CLARK ATLANTA UNIVERSITY
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

Problems solved by technology

The technical problem addressed in this patent is how to reduce the incidence of progression towards advanced stage cancer without causing harmful side effects like radiation failure or secondary carcinogenesis caused by the use of drugs called taxanes and vinca natives despite being able to target specific molecules involved in proliferative processes.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Camalexin as a treatment for prostate cancer
  • Camalexin as a treatment for prostate cancer
  • Camalexin as a treatment for prostate cancer

Examples

Experimental program
Comparison scheme
Effect test

examples

Reagents and Antibodies

[0050]Camalexin (40 mM in absolute ethanol) was synthesized as described in Ayer W A, et al., (1992) Synthesis of camalexin and related phytoalexins. Tetrahedron 48: 2919-2924.

[0051]Growth media RPMI 1640 (1× with L-glutamine, and without L-glutamine and phenol red), and penicillin-streptomycin were from Mediatech (Manassas, Va.). G418 was from EMD Corp Biosciences, Brookfield, Wis. Fetal bovine serum (FBS) and charcoal / dextran treated PBS (DCC-FBS) were from Hyclone, South Logan, Utah. Trypsin / EDTA was from Mediatech, Inc., Manassas, Va. MTS Cell Titer 96 Aqueous One Solution reagent was from Promega Corporation, Madison, Wis. N-acetyl cysteine (NAC) and mouse monoclonal anti-human actin antibody were from Sigma-Aldrich Inc., St Louis, Mo. Rabbit monoclonal anti-cleaved poly (ADP-ribose) polymerase (PARP) primary antibody was from Cell Signaling Technology, Inc., Danvers, Mass. Rabbit polyclonal anti-caspase3 primary antibody was from Santa Cruz Biotechnolog

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Pharmaceutically acceptableaaaaaaaaaa
Effective doseaaaaaaaaaa
Cell viabilityaaaaaaaaaa
Login to view more

Abstract

Compositions and methods to treat prostate cancer with the compound camalexin and its structural analogs. Camalexin increases ROS production and decreases the proliferation of prostate cancer cells, especially aggressive prostate cancer cells.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Owner CLARK ATLANTA UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products